BACKGROUND
 Patients with advanced cancers, who were previously tested for BRAF V600 (42), KRAS G12/G13 (34), or both mutations (1) in the tumor samples (primary or metastatic) in a CLIA-certified laboratory during their clinical care were prospectively enrolled DNA from plasma (3-4ml) from patients with advanced cancers who progressed on systemic therapy were tested for BRAF V600 and KRAS G12 and G13 mutations using the ICE COLD-PCR platform  ICE COLD-PCR, "Improved and Complete Enrichment COamplification at Lower Denaturation" selectively amplifies mutant DNA by exploiting differences in denaturation temperatures between mutant DNA duplexes and normal "wild-type" DNA duplexes  KRAS Exon 2 and BRAF Exon 15 ICE COLD-PCR was performed on plasma samples  Amplicons were analyzed by Sanger sequencing methods and results were compared to the mutation status of the archival primary or metastatic tumor tissue as determined in a CLIA-certified lab
